 SAN DIEGO, Aug. 12, 2021 GLOBE NEWSWIRE -- Metacrine, Inc. NASDAQ:MTCR, a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results. 